The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models

[1]  Herbert Yu,et al.  Ursodeoxycholic acid accelerates bile acid enterohepatic circulation , 2019, British journal of pharmacology.

[2]  W. Kong,et al.  Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters , 2019, Acta pharmaceutica Sinica. B.

[3]  William H. Bisson,et al.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin , 2018, Nature Medicine.

[4]  F. Lammert,et al.  Genetics of gallstone disease , 2018, European journal of clinical investigation.

[5]  Meijing Liu,et al.  Prevention of cholesterol gallstone disease by schaftoside in lithogenic diet‐induced C57BL/6 mouse model , 2017, European journal of pharmacology.

[6]  H. C. Santvoort,et al.  Conservative treatment of acute cholecystitis: a systematic review and pooled analysis , 2017, Surgical Endoscopy.

[7]  B. M. Forman,et al.  Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. , 2016, Bioorganic & medicinal chemistry.

[8]  Shailendra B. Patel,et al.  Evidence that the adenosine triphosphate‐binding cassette G5/G8‐independent pathway plays a determinant role in cholesterol gallstone formation in mice , 2016, Hepatology.

[9]  Chin-Chen Chang,et al.  Mirizzi Syndrome Due to a Large Radiolucent Gallstone , 2016, The American Journal of Gastroenterology.

[10]  Z. Zuo,et al.  Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid , 2016, Clinical and experimental pharmacology & physiology.

[11]  J. Boyer,et al.  Fibrates and cholestasis , 2015, Hepatology.

[12]  M. Trauner,et al.  Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity , 2015, Journal of hepatology.

[13]  C. Klaassen,et al.  Individual bile acids have differential effects on bile acid signaling in mice. , 2015, Toxicology and applied pharmacology.

[14]  Shuodong Wu,et al.  Cholesterol gallstone disease: focusing on the role of gallbladder , 2015, Laboratory Investigation.

[15]  Yen-Chun Chen,et al.  The Prevalence and Risk Factors for Gallstone Disease in Taiwanese Vegetarians , 2014, PloS one.

[16]  J. Chiang,et al.  Bile Acid Signaling in Metabolic Disease and Drug Therapy , 2014, Pharmacological Reviews.

[17]  Hui Tang,et al.  Cholelithiasis and risk of pancreatic cancer: systematic review and meta-analysis of 21 observational studies , 2014, Cancer Causes & Control.

[18]  D. Rader,et al.  Opposing effects of ABCG5/8 function on myocardial infarction and gallstone disease. , 2014, Journal of the American College of Cardiology.

[19]  B. Nordestgaard,et al.  The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease. , 2014, Journal of the American College of Cardiology.

[20]  Soo‐Young Choi,et al.  Cooperative transcriptional activation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 genes by nuclear receptors including Liver-X-Receptor , 2013, BMB reports.

[21]  R. Green,et al.  Hepatic overexpression of Abcb11 in mice promotes the conservation of bile acids within the enterohepatic circulation. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[22]  J. Stindt,et al.  The bile salt export pump (BSEP) in health and disease. , 2012, Clinics and research in hepatology and gastroenterology.

[23]  M. Roma,et al.  Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. , 2011, Clinical science.

[24]  F. Lammert,et al.  Dissecting the Genetic Heterogeneity of Gallbladder Stone Formation , 2011, Seminars in liver disease.

[25]  J. Chiang,et al.  Overexpression of cholesterol 7α‐hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis , 2011, Hepatology.

[26]  J. Everhart,et al.  Gallstone disease is associated with increased mortality in the United States. , 2011, Gastroenterology.

[27]  F. Lammert,et al.  Transgenic overexpression of Abcb11 enhances biliary bile salt outputs, but does not affect cholesterol cholelithogenesis in mice , 2010, European journal of clinical investigation.

[28]  J. Boyer,et al.  Nuclear factor erythroid 2–related factor 2 is a positive regulator of human bile salt export pump expression , 2009, Hepatology.

[29]  Jerzy Bełtowski,et al.  Liver X receptors (LXR) as therapeutic targets in dyslipidemia. , 2008, Cardiovascular therapeutics.

[30]  C. Kahn,et al.  Hepatic insulin resistance directly promotes formation of cholesterol gallstones , 2008, Nature Medicine.

[31]  S. Fukumoto.  Actions and mode of actions of FGF19 subfamily members. , 2008, Endocrine journal.

[32]  J. Auwerx,et al.  Compromised Intestinal Lipid Absorption in Mice with a Liver-Specific Deficiency of Liver Receptor Homolog 1 , 2007, Molecular and Cellular Biology.

[33]  J. Auwerx,et al.  In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. , 2007, Molecular endocrinology.

[34]  J. Behar,et al.  Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones , 2006, Gut.

[35]  J. Auwerx,et al.  Endocrine functions of bile acids , 2006, The EMBO journal.

[36]  K. Erpecum,et al.  Biliary lipids, water and cholesterol gallstones , 2005 .

[37]  Jonathan C. Cohen,et al.  ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol Excretion* , 2003, Journal of Biological Chemistry.

[38]  Jonathan C. Cohen,et al.  Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. , 2002, The Journal of clinical investigation.

[39]  H. Hobbs,et al.  Regulation of ATP-binding Cassette Sterol Transporters ABCG5 and ABCG8 by the Liver X Receptors α and β* , 2002, The Journal of Biological Chemistry.

[40]  B Staels,et al.  Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[41]  J. Chiang,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. , 2000, Journal of lipid research.

[42]  D. Russell,et al.  Nuclear Orphan Receptors Control Cholesterol Catabolism , 1999, Cell.

[43]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[44]  J. Miquel,et al.  Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. , 1998, Gastroenterology.

[45]  D. Mangelsdorf,et al.  An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.

[46]  Z. Halpern,et al.  Effect of phospholipids and their molecular species on cholesterol solubility and nucleation in human and model biles. , 1993, Gut.

[47]  B. Wolfe,et al.  Laparoscopic Cholecystectomy: A Remarkable Development. , 1991, JAMA.

[48]  M. Carey.  Critical tables for calculating the cholesterol saturation of native bile. , 1978, Journal of lipid research.

[49]  F. Lammert,et al.  Gallstone disease: from genes to evidence-based therapy. , 2008, Journal of hepatology.

[50]  K. V. van Erpecum.  Biliary lipids, water and cholesterol gallstones. , 2005, Biology of the cell.

[51]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[52]  H. Hobbs,et al.  Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. , 2002, The Journal of biological chemistry.

[53]  F. Lammert,et al.  Chromosomal organization of candidate genes involved in cholesterol gallstone formation: a murine gallstone map. , 2001, Gastroenterology.